XGEN:XETRA:XETRA-Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C USD Acc (EUR)

ETF | Others |

Last Closing

USD 28.665

Change

+0.04 (+0.12)%

Market Cap

N/A

Volume

1.96K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.06 (-0.11%)

USD 501.76B
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.06 (-0.11%)

USD 501.76B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.02 (-0.15%)

USD 191.96B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.02 (-0.15%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.03 (-0.11%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.03 (-0.11%)

USD 177.46B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.03 (-0.11%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.03 (-0.11%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.10 (-0.39%)

USD 157.79B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.10 (-0.39%)

USD 157.79B

ETFs Containing XGEN:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.79% 42% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.79% 41% F 45% F
Trailing 12 Months  
Capital Gain 10.51% 37% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.51% 37% F 41% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.01% N/A N/A 25% F
Dividend Return -1.01% N/A N/A 24% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 4.03% N/A N/A 93% A
Risk Adjusted Return -25.00% N/A N/A 20% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike